IDO1 and cancer: Rizhen Huang et al. also developed naphthoquinone aromatic amide oxime compounds that can target both STAT3 and indoleamine-2,3-dioxygenase 1 (IDO1) for joint anti-cancer therapy and immunotherapy [147].